Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Variation in enzymes of arylamine procarcinogen biotransformation among bladder cancer patients and control subjects.
Vaziri SA, Hughes NC, Sampson H, Darlington G, Jewett MA, Grant DM. Vaziri SA, et al. Pharmacogenetics. 2001 Feb;11(1):7-20. doi: 10.1097/00008571-200102000-00002. Pharmacogenetics. 2001. PMID: 11207033
Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors.
Vaziri SA, Kim J, Ganapathi MK, Ganapathi R. Vaziri SA, et al. Curr Oncol Rep. 2010 Mar;12(2):102-8. doi: 10.1007/s11912-010-0085-4. Curr Oncol Rep. 2010. PMID: 20425594 Review.
Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib.
Kim JJ, Vaziri SA, Rini BI, Elson P, Garcia JA, Wirka R, Dreicer R, Ganapathi MK, Ganapathi R. Kim JJ, et al. Among authors: vaziri sa. Cancer. 2012 Apr 1;118(7):1946-54. doi: 10.1002/cncr.26491. Epub 2011 Aug 31. Cancer. 2012. PMID: 21882181 Free PMC article.
CCL2 expression in primary ovarian carcinoma is correlated with chemotherapy response and survival outcomes.
Fader AN, Rasool N, Vaziri SA, Kozuki T, Faber PW, Elson P, Biscotti CV, Michener CM, Rose PG, Rojas-Espaillat L, Belinson JL, Ganapathi MK, Ganapathi R. Fader AN, et al. Among authors: vaziri sa. Anticancer Res. 2010 Dec;30(12):4791-8. Anticancer Res. 2010. PMID: 21187454
Inhibition of proteasome activity by bortezomib in renal cancer cells is p53 dependent and VHL independent.
Vaziri SA, Grabowski DR, Hill J, Rybicki LR, Burk R, Bukowski RM, Ganapathi MK, Ganapathi R. Vaziri SA, et al. Anticancer Res. 2009 Aug;29(8):2961-9. Anticancer Res. 2009. PMID: 19661301 Free PMC article.
Inhibition of NF-kappaB and proteasome activity in tumors: can we improve the therapeutic potential of topoisomerase I and topoisomerase II poisons.
Ganapathi R, Vaziri SA, Tabata M, Takigawa N, Grabowski DR, Bukowski RM, Ganapathi MK. Ganapathi R, et al. Among authors: vaziri sa. Curr Pharm Des. 2002;8(22):1945-58. doi: 10.2174/1381612023393549. Curr Pharm Des. 2002. PMID: 12171521 Review.
Differing von hippel lindau genotype in paired primary and metastatic tumors in patients with clear cell renal cell carcinoma.
Vaziri SA, Tavares EJ, Golshayan AR, Rini BI, Aydin H, Zhou M, Sercia L, Wood L, Ganapathi MK, Bukowski RM, Ganapathi R. Vaziri SA, et al. Front Oncol. 2012 May 28;2:51. doi: 10.3389/fonc.2012.00051. eCollection 2012. Front Oncol. 2012. PMID: 22655276 Free PMC article.
von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma.
Choueiri TK, Vaziri SA, Jaeger E, Elson P, Wood L, Bhalla IP, Small EJ, Weinberg V, Sein N, Simko J, Golshayan AR, Sercia L, Zhou M, Waldman FM, Rini BI, Bukowski RM, Ganapathi R. Choueiri TK, et al. Among authors: vaziri sa. J Urol. 2008 Sep;180(3):860-5; discussion 865-6. doi: 10.1016/j.juro.2008.05.015. Epub 2008 Jul 17. J Urol. 2008. PMID: 18635227
Proteasome inhibition with bortezomib enhances activity of topoisomerase I-targeting drugs by NF-kappaB-independent mechanisms.
Takigawa N, Vaziri SA, Grabowski DR, Chikamori K, Rybicki LR, Bukowski RM, Ganapathi MK, Ganapathi R, Mekhail T. Takigawa N, et al. Among authors: vaziri sa. Anticancer Res. 2006 May-Jun;26(3A):1869-76. Anticancer Res. 2006. PMID: 16827119 Free article.
Sensitization of DNA damage-induced apoptosis by the proteasome inhibitor PS-341 is p53 dependent and involves target proteins 14-3-3sigma and survivin.
Vaziri SA, Hill J, Chikamori K, Grabowski DR, Takigawa N, Chawla-Sarkar M, Rybicki LR, Gudkov AV, Mekhail T, Bukowski RM, Ganapathi MK, Ganapathi R. Vaziri SA, et al. Mol Cancer Ther. 2005 Dec;4(12):1880-90. doi: 10.1158/1535-7163.MCT-05-0222. Mol Cancer Ther. 2005. PMID: 16373703 Free article.
17 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback